DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Pelzer U, Blanc JF, Melisi D. et al.
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
Br J Cancer 2017;
116: 1247-1253
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.